4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Current Assets of $405.4 million for Q1 2026, up 21.89% year-over-year from $332.6 million in Q1 2025, and down 1.88% quarter-over-quarter from $413.1 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Current Assets (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Current Assets for 8 consecutive years, with $405.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 21.89% year-over-year to $405.4 million; the TTM figure through Mar 2026 stood at $405.4 million (up 21.89% YoY), while the FY2025 annual figure was $413.1 million, down 5.01% from the prior year.
- Current Assets slipped to $405.4 million in Q1 2026 per FDMT's latest filing, from $413.1 million in the prior quarter.
- Across five years, Current Assets topped out at $552.6 million in Q2 2024 and bottomed at $207.0 million in Q1 2023.
- Historically, Current Assets has averaged $346.6 million across 5 years, with a median of $317.8 million in 2023.
- Annual changes were most pronounced in 2024 — Current Assets surged 158.69% — and 2025, when it sank 45.12%.
- 4D Molecular Therapeutics' Current Assets stood at $220.5 million in 2022, then jumped by 34.5% to $296.6 million in 2023, then jumped by 46.65% to $434.9 million in 2024, then retreated by 5.01% to $413.1 million in 2025, then decreased by 1.88% to $405.4 million in 2026.
- Business Quant data shows FDMT's Current Assets at $405.4 million in Q1 2026, $413.1 million in Q4 2025, and $312.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 382.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 382.96 Mn |
| Mar 31, 2026 | 405.36 Mn |
| Dec 31, 2025 | 413.13 Mn |
| Sep 30, 2025 | 312.38 Mn |
| Jun 30, 2025 | 303.29 Mn |
| Mar 31, 2025 | 332.57 Mn |
| Dec 31, 2024 | 434.93 Mn |
| Sep 30, 2024 | 510.76 Mn |
| Jun 30, 2024 | 552.63 Mn |
| Mar 31, 2024 | 535.59 Mn |
| Dec 31, 2023 | 296.59 Mn |
| Sep 30, 2023 | 328.24 Mn |
| Jun 30, 2023 | 317.78 Mn |
| Mar 31, 2023 | 207.04 Mn |
| Dec 31, 2022 | 220.51 Mn |
| Sep 30, 2022 | 232.48 Mn |
| Jun 30, 2022 | 246.52 Mn |
| Mar 31, 2022 | 243.05 Mn |
| Dec 31, 2021 | 256.28 Mn |
| Sep 30, 2021 | 165.73 Mn |